Article
Oncology
Min-Ji Yoon, Hwijae Cha, Jungho Ahn, Danbi Lee, Hyun-Seok Jeong, Hwa Seon Koo, Youn-Jung Kang
Summary: Ovarian cancer is the deadliest gynecological malignancy worldwide, and resistance to genotoxic stress may be a critical cause of chemoresistance in patients.
Article
Biochemistry & Molecular Biology
Zhiyuan Dou, Chunping Qiu, Xun Zhang, Shu Yao, Chen Zhao, Zixiang Wang, Ran Chu, Jingying Chen, Zhongshao Chen, Rongrong Li, Kun Wang, Penglin Liu, Chang Liu, Kun Song, Beihua Kong
Summary: This study found that HJURP is overexpressed in ovarian cancer and is associated with unfavorable prognosis. Knockdown of HJURP inhibits proliferation, metastasis, and induces cell stagnation in ovarian cancer cells. Mechanistically, HJURP regulates WEE1 through the MYC pathway, affecting chemosensitivity and DNA repair in ovarian cancer cells. Moreover, silencing HJURP enhances sensitivity to cisplatin and improves the synergistic effect of combined therapy with cisplatin and AZD1775 in ovarian cancer cells.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Cell Biology
Shanyu Fang, Yuanyuan Luo, Ying Zhang, Houmei Wang, Qianfen Liu, Xinya Li, Tinghe Yu
Summary: In the treatment of epithelial ovarian cancer, a high level of NTNG1 has been found to lead to cisplatin resistance through the GAS6/AXL/Akt pathway, affecting cell apoptosis and survival. NTNG1 may serve as a useful target to overcome drug resistance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Oliver Zivanovic, Dennis S. Chi, Qin Zhou, Alexia Iasonos, Jason A. Konner, Vicky Makker, Rachel N. Grisham, Amy K. Brown, Stacy Nerenstone, John P. Diaz, Eric D. Schroeder, Carrie L. Langstraat, Viktoriya Paroder, Yulia Lakhman, Krysten Soldan, Katy Su, Ginger J. Gardner, Vaagn Andikyan, Jianxia Guo, Elizabeth L. Jewell, Kara Long Roche, Tiffany Troso-Sandoval, Stuart M. Lichtman, Lea A. Moukarzel, Kimberly Dessources, Nadeem R. Abu-Rustum, Carol Aghajanian, William P. Tew, Jan Beumer, Yukio Sonoda, Roisin E. O'Cearbhaill
Summary: In this study, while HIPEC with carboplatin achieved a higher rate of complete tumor resection, it did not show superior clinical outcomes compared to standard treatment, challenging the use of carboplatin HIPEC during secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Cell Biology
Ricardo Coelho, Alessandra Tozzi, Muriel Disler, Flavio Lombardo, Andre Fedier, Monica Nunez Lopez, Florian Freuler, Francis Jacob, Viola Heinzelmann-Schwarz
Summary: PARP inhibitors have shown outstanding benefits in the treatment of epithelial ovarian cancer, especially in patients with BRCA1/2 mutations or defects in the homologous recombination repair system. This study identified ATM, MUS81, NBN, BRCA2, and RAD51B as predictive markers for olaparib response and highlighted CDK12 as a potential therapeutic target in EOC.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Jian-Lei Zhao, Jun Yang, Ke Li, Yang Chen, Mei Tang, Hui -Li Zhu, Chun-Lai Nie, Zhu Yuan, Xin-Yu Zhao
Summary: Targeting replication stress response is a promising therapeutic strategy for breast tumors, and combination therapy of ATR inhibitor and cisplatin may offer potential benefits.
CHEMICO-BIOLOGICAL INTERACTIONS
(2023)
Article
Chemistry, Medicinal
Mengdi Song, Mingxiao Cui, Kehai Liu
Summary: This review discusses the chemotherapeutic drugs and phytochemicals developed to overcome cisplatin-resistance ovarian cancer (CROC), highlighting the significance of combination therapy and the use of a nanoparticle delivery system in reversing cisplatin resistance.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Cell Biology
Hanlin Ma, Gonghua Qi, Fang Han, Wei Lu, Jiali Peng, Rongrong Li, Shi Yan, Cunzhong Yuan, Beihua Kong
Summary: This study found that the overexpression of HMGB3 is associated with shorter overall survival and drug resistance in high-grade serous ovarian carcinoma. HMGB3 interacts with PARP1 to promote PARPi resistance, and targeted inhibition of HMGB3 may overcome PARPi resistance in ovarian cancer therapy.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Josef Horak, Alexandra Dolnikova, Ozge Cumaogullari, Andrea Cumova, Nazila Navvabi, Ludmila Vodickova, Miroslav Levy, Michaela Schneiderova, Vaclav Liska, Ladislav Andera, Pavel Vodicka, Alena Opattova
Summary: Cancer therapy failure is a major challenge in cancer treatment, with acquired resistance being one of the most common reasons for it. This study suggests that miR-140 may act as a tumor suppressor and play an important role in the response to oxaliplatin therapy in colorectal cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Hongyu Xie, Wenjie Wang, Wencai Qi, Weilin Jin, Bairong Xia
Summary: Combining DDR inhibitors with ICI therapy in ovarian cancer can enhance local antigen release, promote systemic antitumor immune responses, and potentially improve clinical outcomes for patients with ovarian cancer. This combination therapy strategy is based on the interconnectivity between DDR pathway deficiency and immune response, and it is supported by available clinical trials and potential predictive biomarkers.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Marcin Michalak, Michel S. Lach, Sylwia Borska, Blazej Nowakowski, Kazuo Umezawa, Wiktoria M. Suchorska
Summary: Ovarian cancer is a lethal gynaecological malignancy with a reduced survival rate due to difficulty in early detection and chemoresistance. Activation of the NF-kappa B signalling pathway is associated with poor prognosis in patients. Developing inhibitors for this pathway has become a target in cancer therapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Jaemoo Chun
Summary: Isoalantolactone, a compound derived from Inula helenium L., has been identified as a potential glycolysis inhibitor to overcome cisplatin resistance in ovarian cancer. It effectively targets key glycolytic enzymes and enhances sensitivity to cisplatin-induced apoptosis. In vivo studies demonstrate its ability to suppress tumor growth in cisplatin-resistant ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Nanoscience & Nanotechnology
Miaojuan Qiu, Junzong Chen, Xiuyu Huang, Binbin Li, Shiqiang Zhang, Peng Liu, Qiang Wang, Zhi Rong Qian, Yihang Pan, Yu Chen, Jing Zhao
Summary: This study successfully achieved synergistic treatment for intraperitoneally disseminated ovarian cancer by using RGD-modified amorphous calcium phosphate loaded with doxorubicin. The engineered calcium-involved nanomedicine augmented the therapeutic effect of doxorubicin and showed favorable anti-tumor effects in an experimental model.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Medicine, General & Internal
Ibrahim Azar, Omid Yazdanpanah, Hyejeong Jang, Adam Austin, Seongho Kim, Jie Chi, Samer Alkassis, Biplab K. Saha, Amit Chopra, Kristoffer Neu, Syed Mehdi, Hirva Mamdani
Summary: There is no significant difference in survival outcomes between cisplatin and carboplatin for the treatment of both limited-stage and extensive-stage small cell lung cancer (SCLC). The favorable toxicity profile of carboplatin and comparable overall survival support its use in clinical practice for both types of SCLC and allow for combination with novel treatment strategies in clinical trials.
Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Obstetrics & Gynecology
Erin A. Blake, Chrystal A. Bradley, Sayedamin Mostofizadeh, Franco M. Muggia, Agustin A. Garcia, Lynda D. Roman, Koji Matsuo
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2019)
Article
Obstetrics & Gynecology
Peter G. Rose, Janzes J. Java, Ritu Salani, Melissa A. Geller, Angeles Alvarez Secord, Krishnansu S. Tewari, David P. Bender, David G. Mutch, Michael L. Friedlander, Linda Van Le, Michael W. Method, Chad A. Hamilton, Roger B. Lee, Robert M. Wenham, Saketh R. Guntupalli, Maurie Markman, Franco M. Muggia, Deborah K. Armstron, Michael A. Bookman, Robert A. Burger, Lally J. Copeland
OBSTETRICS AND GYNECOLOGY
(2019)
Article
Oncology
Olivia R. Khouri, Melissa K. Frey, Fernanda Musa, Franco Muggia, Jessica Lee, Leslie Boyd, John P. Curtin, Bhavana Pothuri
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2019)
Article
Oncology
Koji Matsuo, Rachel S. Mandelbaum, Hiroko Machida, Kosuke Yoshihara, Franco M. Muggia, Lynda D. Roman, Jason D. Wright
GYNECOLOGIC ONCOLOGY
(2019)
Meeting Abstract
Oncology
Kenneth Evan Fleisher, Franco Muggia, Robert S. Glickman
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Medicine, General & Internal
Koji Matsuo, Rachel S. Mandelbaum, Hiroko Machida, Kosuke Yoshihara, Anco M. Muggia, Lynda D. Roman, Jason D. Wright
JOURNAL OF CLINICAL MEDICINE
(2019)
Meeting Abstract
Oncology
B. Pothuri, Z. Sawaged, J. Lee, F. Musa, K. Lutz, E. Reese, S. V. Blank, L. R. Boyd, J. P. Curtin, X. Li, J. D. Goldberg, F. M. Muggia
GYNECOLOGIC ONCOLOGY
(2019)
Article
Oncology
Bhavana Pothuri, Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman, Amy Tiersten, Brian F. Kiesel, Jan H. Beumer, Leonard Liebes, Franco Muggia
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2020)
Article
Medicine, Research & Experimental
Lindsey E. Moses, Janine M. Rotsides, Fiyinfolu O. Balogun, Mark S. Persky, Franco M. Muggia, Michael J. Persky
Article
Obstetrics & Gynecology
Koji Matsuo, Rachel S. Mandelbaum, Hiroko Machida, Kosuke Yoshihara, Shinya Matsuzaki, Maximilian Klar, Franco M. Muggia, Lynda D. Roman, Jason D. Wright
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2020)
Editorial Material
Oncology
Franco Muggia
Article
Oncology
Tamar Safra, Barliz Waissengrin, Deanna Gerber, Rinat Bernstein-Molho, Geula Klorin, Lina Salman, Dana Josephy, Rakefet Chen-Shtoyerman, Ilan Bruchim, Melissa K. Frey, Bhavana Pothuri, Franco Muggia
Summary: The study evaluated the incidence of breast cancer and overall survival in ovarian cancer patients carrying BRCA1/2 mutations. It found that routine breast surveillance may be sufficient in ovarian cancer survivors, as the incidence of breast cancer after ovarian cancer was low in BRCA1/2 mutation carriers.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
Andrey Moiseyenko, Franco Muggia, Thomas Condamine, Jennifer Pulini, John E. Janik, Daniel C. Cho
GYNECOLOGIC ONCOLOGY REPORTS
(2020)
Article
Oncology
Evgenia Granina, Julia Fehniger, Douglas Kondziolka, Joshua Silverman, Andrea Downey, Dimitris Placantonakis, Franco Muggia
ECANCERMEDICALSCIENCE
(2020)
Article
Oncology
Pooja Murthy, Franco Muggia
ECANCERMEDICALSCIENCE
(2019)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)